>>> Hess beats by $0.20, beats on revs

Hess beats by $0.20, beats on revs

Reports Q2 (Jun) loss of $0.52 per share, $0.20 better than the Capital IQ Consensus Estimate of ($0.72). Co reported revenues of $1.936 bln may not compare to $1.635 bln
  • Oil and gas production increased to 391,000 barrels of oil equivalent per day compared to 319,000 boepd in the second quarter of 2014. Capital and exploratory expenditures totaled $1.1 billion in the second quarter down from $1.3 billion in the prior-year quarter

>>> Hospira beats by $0.05, reports revs in-line

Hospira beats by $0.05, reports revs in-line

Reports Q2 (Jun) earnings of $0.85 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.80; revenues rose 4.2% year/year to $1.18 bln vs the $1.18 bln consensus.
  • Given the announcement early in Q1 that Hospira and Pfizer (PFE) had entered into a merger agreement, the company is not providing annual projections for 2015.
  • "Hospira continues to see good momentum across our product lines, resulting in strong sales and profitability in the first half of the year...Complementing our strong financial performance is our continued progress on many fronts, including new generic injectable product launches, advancements in our on-market biosimilars and related pipeline, and execution of our Device Strategy."

>>> Humana beats by $0.04; guides Q3 EPS in-line; reaffirms FY15 EPS guidance; a

Humana beats by $0.04; guides Q3 EPS in-line; reaffirms FY15 EPS guidance; as previously announced, being acquired by AET

Reports Q2 (Jun) earnings of $1.67 per share, $0.04 better than the Capital IQ Consensus Estimate of $1.63.
  • Co issues in-line guidance for Q3, sees EPS of $2.15 vs. $2.16 Capital IQ Consensus Estimate.
  • Co reaffirms guidance for FY15, sees EPS of $7.75 vs. $7.77 Capital IQ Consensus Estimate.
  • On July 3, 2015, the company announced it entered into a definitive agreement with Aetna Inc. (AET) under which Aetna will acquire all outstanding shares of Humana for a combination of cash and stock. Under terms of the agreement, Humana stockholders will receive $125 in cash and 0.8375 of an Aetna common share for each Humana share.

>>> Early premarket gappers

Early premarket gappers
Gapping up: CYT +25.9%, NHTC +21.1%, STLY +19.8%, OGEN +19%, RUBI +17.1%, NGD +17%, CALX +14.3%, AIZ +9.6%, BWLD +9.5%, BBSI +8.5%, PNRA +7.9%, RSYS +7.4%, ATRC +5.9%, WNC +5.1%, CETV +4.9%, CTXS +4.8%, BLDP +4.3%, NUVA +4.1%, GILD +4%, ACCO +3.1%, AMED +3%, RGR +2.9%, TRU +2.6%, STO +2.5%, ANTM +2.4%, BCS+2.1%, GG +1.7%, AKS +1.7%, IACI +1.7%, ESRX +1.6%, HLT +1.5%, MO +1.5%, PYPL +1.3%, HURN +1.3%, AMZN +1%, NCR +1%, APC +0.9%

Gapping down: YELP -20.3%, SFY -13.7%, VDSI -10.1%, GIGA -9.8%, TWTR -9.2%, AKAM -7.7%, ZGNX -5.7%, BBOX -5.1%, CG -3.9%, IPHI -3.1%, RRC -2.8%, SLCA -2.4%, X -2.4%, PPP -2.2%, AFL -2.1%, MT -1.8%, CRI -1.8%, HA -1.7%, CBZ -1.4%, GIB -1.2%, RIG -1.1%, Q -1%, SPWR -0.5%

>>> General Dynamics beats by $0.22, beats on revs; Raises FY15 EPS guidance abo

General Dynamics beats by $0.22, beats on revs; Raises FY15 EPS guidance above consensus

Reports Q2 (Jun) earnings of $2.27 per share, $0.22 better than the Capital IQ Consensus Estimate of $2.05; revenues rose 5.5% year/year to $7.88 bln vs the $7.68 bln consensus. Co issues upside guidance for FY15, sees EPS of $8.70-8.80 vs. $8.61 Capital IQ Consensus Estimate.

Backlog
General Dynamics' backlog remained steady at the end of second-quarter 2015, with funded backlog at $55.4 billion and total backlog of $70 billion. Aerospace backlog increased by seven percent in the quarter, with strong order activity across the product line. Information Systems and Technology also had several notable orders in the quarter leading to higher backlog. Estimated potential contract value, representing management's estimate of value in unfunded indefinite delivery, indefinite quantity (IDIQ) contracts and unexercised options, was $25.6 billion. Total potential contract value, the sum of all backlog components, was $95.6 billion at the end of the quarter.

>>> CNH Industrial misses by $0.06, misses on revs; reaffirms sales, lower margi

--> -4%

CNH Industrial misses by $0.06, misses on revs; reaffirms sales, lower margin guidance (
Reports Q2 (Jun) adj. earnings of $0.11 per share, €0.06 worse than the Capital IQ Consensus of $0.17; revenues fell 21.9% year/year to $6.96 bln vs the $7.48 bln consensus.
  • Full year guidance updated as follows: net sales of Industrial Activities in the range of $26-27 billion, with operating margin of Industrial Activities between 5.6% and 6.0% (from 6.1-6.4%) and net industrial debt at the end of 2015 between $2.0 billion and $2.2 billion.

>>> GlaxoSmithKline reports EPS in-line, revs in-line; provides FY15 and FY16 gu

--> +4%

GlaxoSmithKline reports EPS in-line, revs in-line; provides FY15 and FY16 guidance
Reports Q2 (Jun) core earnings of GBP0.17 per share, in-line with the Capital IQ Consensus Estimate of GBP0.17; revenues rose 5.9% year/year to GBP5.89 bln vs the GBP5.88 bln consensus.
  • FY15 Guidance: Core EPS for 2015 is expected to decline at a percentage rate in the high teens (Capital IQ consensus -16%) primarily due to continued pricing pressure on Seretide/Advair in US/Europe, the dilutive effect of the Novartis transaction and the inherited cost base of the Novartis businesses.
  • FY16 Guidance: In 2016, GSK expects to see a significant recovery in core EPS with percentage growth expected to reach double digits on a CER basis as the adverse impacts seen in 2015 diminish and the sales and synergy benefits of the Novartis transaction contribute more meaningfully.

>>> RPC misses by $0.05, reports revs in-line (oil&gas services)

RPC misses by $0.05, reports revs in-line

Reports Q2 (Jun) loss of $0.16 per share, $0.05 worse than the Capital IQ Consensus Estimate of ($0.11); revenues fell 48.9% year/year to $297.6 mln vs the $299.11 mln consensus.
  • "RPC's financial results during Q2 of 2015 reflect our industry's declining activity levels and competitive pricing for our services," stated Richard A. Hubbell, RPC's President and Chief Executive Officer.
  • "The average U.S. domestic rig count during Q2 was 907, a decrease of 51.1% compared to the same period in 2014, and a decrease of 35.4% compared to Q1 of 2015. The average price of natural gas was $2.70 per Mcf, a 40.7% decrease compared to the prior year, and a 4.3% decrease compared to Q1 of 2015. The unconventional rig count declined by 45.6% compared to the prior year and 33.1% sequentially. The average price of oil during the quarter was $57.53 per barrel, a 44.3% decrease compared to the prior year but a 17.4% increase compared to the first quarter of 2015. Our sequential revenue decline was slightly less than overall industry declines because of the increasing service intensity of pressure pumping, which is RPC's largest service line."

>>> Altria beats by $0.03, beats on revs; guides FY15 EPS in-line; Announces $1

Altria beats by $0.03, beats on revs; guides FY15 EPS in-line; Announces $1 bln share buyback

Reports Q2 (Jun) earnings of $0.74 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus Estimate of $0.71; revenues rose 5.7% year/year to $6.61 bln, which may not be comparable to the $4.75 bln consensus. Co issues in-line guidance for FY15, sees EPS of $2.76-2.81 vs. $2.81 Capital IQ Consensus Estimate. Altria expects its adjusted diluted EPS growth to moderate in the second half of 2015 versus the first-half rate due to several factors. These include lapping the effects of the 2014 improvements in the economy for adult tobacco consumers and lower gasoline prices, expected trade inventory movements and the effect of state excise tax increases. In addition, the comparative benefit from the expiration of the federal tobacco quota buy-out payments ends in the fourth quarter and Altria now estimates its 2015 full-year effective tax rate on operations will be 35.3%.

>>> Praxair reports EPS in-line, misses on revs; guides Q3 EPS below consensus;

Praxair reports EPS in-line, misses on revs; guides Q3 EPS below consensus; lowers FY15 EPS below consensus

  • Reports Q2 (Jun) earnings of $1.45 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $1.45; revenues fell 12.0% year/year to $2.74 bln vs the $2.85 bln consensus, primarily due to the impact of negative currency translation of 9% and lower cost pass-through of 2%. Organic sales were 1% lower than the prior-year quarter as positive price and new project contribution were offset by weaker underlying industrial activity in Brazil and China and from weaker metals, energy and manufacturing in the United States.
  • Co issues downside guidance for Q3, sees EPS of $1.42-1.49, excluding non-recurring items, vs. $1.57 Capital IQ Consensus Estimate.
  • Co issues downside guidance for FY15, lowers EPS to $5.80-5.95, excluding non-recurring items, from $5.90-6.15 vs. $5.99 Capital IQ Consensus Estimate.